US 12,275,702 B2
Methods of treating mood disorders
Andrew Carry Kruegel, Secaucus, NJ (US)
Assigned to GILGAMESH PHARMACEUTICALS, INC., New York, NY (US)
Filed by Gilgamesh Pharmaceuticals, Inc., New York, NY (US)
Filed on May 31, 2024, as Appl. No. 18/680,473.
Application 18/680,473 is a continuation of application No. 17/404,923, filed on Aug. 17, 2021.
Application 17/404,923 is a continuation in part of application No. PCT/US2021/018534, filed on Feb. 18, 2021.
Claims priority of provisional application 62/978,075, filed on Feb. 18, 2020.
Prior Publication US 2024/0317683 A1, Sep. 26, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 209/16 (2006.01); A61K 31/4045 (2006.01); A61P 25/24 (2006.01); A61P 25/28 (2006.01)
CPC C07D 209/16 (2013.01) [A61K 31/4045 (2013.01); A61P 25/24 (2018.01); A61P 25/28 (2018.01)] 28 Claims
 
1. A pharmaceutically acceptable salt of a compound wherein the compound has the structure:

OG Complex Work Unit Chemistry
and wherein the pharmaceutically acceptable salt is a hydrochloride, a fumarate, a phosphate, a malate, or a succinate of said compound.